ArticlePharmaceuticals (Basel, Switzerland)2024
RETRACTED: Potential Antitumor Activity of Combined Lycopene and Sorafenib against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation.
Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Preliminary study on the efficacy of pazopanib combined with toripalimab as first-line therapy for metastatic renal cell carcinoma: Real-world data from a single center.Oncology letters · 2026Article
- Exploring the Therapeutic Potential of Lycopene: Mechanisms, Biological Activities, and Health Benefits.International journal of molecular sciences · 2026Review
- RETRACTED: El-Masry et al. Potential Antitumor Activity of Combined Lycopene and Sorafenib Against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Lycopene as a potential anticancer agent: Current evidence on synergism, drug delivery systems and epidemiology (Review).Oncology letters · 2025Review
- Formulation and evaluation of polymeric nanoparticles to improve in vivo chemotherapeutic efficacy of mangiferin against breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy.Food science & nutrition · 2025Review
- Research progress on the signaling pathway mechanism of terpenoids against breast cancer.Discover oncology · 2025Review
- Bioactivity and Bioavailability of Carotenoids Applied in Human Health: Technological Advances and Innovation.International journal of molecular sciences · 2024Review
- Oranges, potatoes and phytonutrients; why are they good for human health.PHYTOnutrients (Karachi, Pakistan) · 2024Article
Corrections and comments
- Retracted
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An FDA-approved kinase inhibitor called sorafenib (SOR) is used to treat primary kidney and liver cancer as well as to stop the spread of advanced breast cancer. Side effects from SOR, such as palmar-plantar erythrodysesthesia syndrome, can negatively impact an individual's quality of life. There are a lot of data supporting the importance of lycopene (LYC) in preventing cancer. The antitumor properties of the combination of sorafenib and lycopene were examined in this study. A viability test against MDA-MB-231 was used to assess the anticancer efficacy of sorafenib, lycopene, and their combination in vitro. Moreover, a cell cycle analysis and Annexin-V/PI double staining were performed by using flow cytometry. In addition, the protein level of JNK-1, ERK-1, Beclin-1, P38, and P53 of the MDA-MB-231 cell line was estimated using ELISA kits. In addition, mice with SEC were divided into four equal groups at random (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.